Finance

Lists
SGMOQ:OTCMKTS
Sangamo Therapeutics Inc
$0.17
-2.81%
(-0.0048) 1D
Sep 3, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGMOQ...
Open
$0.17
High
$0.17
Low
$0.16
Mkt. cap
69.26M
Avg. vol.
3.60M
Volume
2.02M
52-wk high
$0.20
52-wk low
$0.03
EPS
-$0.38
Beta
1.55
Shares outstanding
414.29M
No. of employees
142
Open
$0.17
High
$0.17
Low
$0.16
Mkt. cap
69.26M
Avg. vol.
3.60M
Volume
2.02M
52-wk high
$0.20
52-wk low
$0.03
EPS
-$0.38
Beta
1.55
Shares outstanding
414.29M
No. of employees
142
Profile
Sangamo Therapeutics, Inc. is an American biotechnology company based in Richmond, California, that develops cell and gene therapies for severe genetic diseases. Wikipedia
About Sangamo Therapeutics Inc
CEOSandy Macrae
Employees142
Founded1995
HeadquartersRichmond, California, United States
SectorBiotechnology
Websitesangamo.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
18.31M
581.00K
14.23M
1.44M
Cost of goods sold
27.08M
28.14M
31.44M
26.57M
Cost of revenue
27.08M
28.14M
31.44M
26.57M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.08M
7.99M
7.76M
6.82M
Operating expense
9.08M
7.99M
7.76M
6.82M
Total operating expenses
36.16M
36.13M
39.20M
33.39M
Operating income
-17.86M
-35.55M
-24.97M
-31.95M
Other non operating income
-2.49M
207.00K
-21.00K
-49.00K
EBT including unusual items
-19.96M
-35.09M
-37.97M
-31.00M
EBT excluding unusual items
-19.96M
-35.09M
-24.74M
-31.00M
Income tax expense
27.00K
-161.00K
-553.00K
-
Effective tax rate
-0.14%
0.46%
1.46%
-
Other operating expenses
-
-
-
-
Net income
-19.99M
-34.93M
-37.42M
-31.00M
Net profit margin
-109.18%
-6,012.05%
-263.00%
-2,149.45%
Earnings per share
-0.08
-0.11
-0.07
-0.08
Interest and investment income
386.00K
355.00K
252.00K
300.00K
Interest expense
-
-
-
-
Net interest expenses
386.00K
355.00K
252.00K
300.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-16.86M
-34.56M
-24.01M
-31.23M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps